Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

626 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
Boivin G, Goyette N, Gilbert C, Roberts N, Macey K, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Covington E. Boivin G, et al. Among authors: humar a. J Infect Dis. 2004 May 1;189(9):1615-8. doi: 10.1086/382753. Epub 2004 Apr 13. J Infect Dis. 2004. PMID: 15116297 Clinical Trial.
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.
Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD; Valganciclovir Solid Organ Transplant Study Group. Paya C, et al. Among authors: humar a. Am J Transplant. 2004 Apr;4(4):611-20. doi: 10.1111/j.1600-6143.2004.00382.x. Am J Transplant. 2004. PMID: 15023154 Free article. Clinical Trial.
Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients.
Freeman RB, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Heaton N; Valganciclovir Solid Organ Transplant Study Group. Freeman RB, et al. Among authors: humar a. Transplantation. 2004 Dec 27;78(12):1765-73. doi: 10.1097/01.tp.0000142619.01510.a5. Transplantation. 2004. PMID: 15614149 Clinical Trial.
Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
Wiltshire H, Hirankarn S, Farrell C, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N; Valganciclovir Solid Organ Transplant Study Group. Wiltshire H, et al. Among authors: humar a. Clin Pharmacokinet. 2005;44(5):495-507. doi: 10.2165/00003088-200544050-00003. Clin Pharmacokinet. 2005. PMID: 15871635 Clinical Trial.
626 results